Value20242025TTMSelling/general/admin expenses755.35 M731.74 M731.74 MResearch & development149.32 M172.92 M172.92 MOperating income-691.08 M-252.87 M-252.87 MNon-Operating Income, Total49.5 M47.34 M47.34 MInterest expense, net of interest capitalized53.65 M70.27 M70.27 MNon-Operating Income, excl. Interest Expenses-36.49 M-54.38 M-54.38 MUnusual income/expense32.34 M31.45 M31.45 MPretax income-705.54 M-296.71 M-296.71 MEquity in earnings-4.23 M-5.61 M-5.61 MTaxes266 K-51.68 M-51.68 MNon-controlling/minority interest———After tax other income/expense———Net income before discontinued operations-705.81 M-245.03 M-245.03 MDiscontinued operations———Net income-705.81 M-245.03 M-245.03 MDilution adjustment000Preferred dividends40.52 M00Diluted net income available to common stockholders-746.33 M-245.03 M-245.03 MBasic earnings per share (Basic EPS)-6.23-1.41-1.41Diluted earnings per share (Diluted EPS)-6.23-1.41-1.41Average basic shares outstanding119.85 K174.26 K693.1 KDiluted shares outstanding119.85 K174.26 K693.1 KEBITDA-662.83 M-216.25 M-216.25 MEBIT-691.08 M-252.87 M-252.87 MCost of revenue13.97 M15.15 M15.15 MOther cost of goods sold———Depreciation & amortization (cash flow)28.25 M36.63 M36.63 M
Tempus AI, Inc. Class A
Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."